Key result
Tirofiban infusion significantly decreased the levels of soluble cell adhesion molecules sICAM-1 and sVCAM-1 at 72 hours in patients with unstable angina pectoris compared to standard therapy alone.
Why the study?
Does tirofiban reduce soluble cell adhesion molecules (sICAM-1 and sVCAM-1) in patients with unstable angina pectoris?
Population
55 patients total: 35 with unstable angina pectoris, 10 with stable angina pectoris, and 10 with…
Comparison
Tirofiban added to standard therapy. vs Standard therapy without tirofiban.
Design
Cohort
Follow-up
72 hours
Authors
Loading...
May support anti-inflammatory effects of tirofiban in unstable angina; hypothesis-generating and requires randomized confirmation before practice change.
Observational (n=55)
Does tirofiban reduce soluble cell adhesion molecules (sICAM-1 and sVCAM-1) in patients with unstable angina pectoris?
Absolute Event Rate: 209.7% vs -25%
p-value: p=<0.0001
Tirofiban infusion significantly decreases soluble cell adhesion molecules in patients with unstable angina pectoris, suggesting an anti-inflammatory effect beyond its primary platelet inhibition mechanism.
Ercan et al. (2004) conducted an observational in Unstable angina pectoris (n=55). Tirofiban vs. Standard therapy without tirofiban was evaluated on Change in sICAM-1 levels from baseline to 72 hours (ng/ml) (p=<0.0001). Tirofiban infusion significantly decreased the levels of soluble cell adhesion molecules sICAM-1 and sVCAM-1 at 72 hours in patients with unstable angina pectoris compared to standard therapy alone.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: